Dostarlimab-Gxly Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 500 mg
Reference Brands: Jemperli(USA/EU)
Category: Oncology Cancer Care
Dostarlimab is a humanized monoclonal antibody that targets PD‑1 on T cells, blocking its interaction with PD‑L1/PD-L2. This releases the “brake” on the immune system, allowing T cells to attack cancer cells. It is used mainly for mismatch repair–deficient (dMMR) endometrial cancer and certain other solid tumors with dMMR. Dostarlimab-gxly is available in Injection and strengths such as 500 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Dostarlimab-gxly is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Dostarlimab-gxly can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Dostarlimab-gxly is used for the treatment of certain advanced or recurrent endometrial cancers that are mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H). It helps the immune system recognize and attack cancer cells by blocking the PD-1 receptor.
It is made from a monoclonal antibody that selectively binds to the programmed death-1 (PD-1) receptor on T-cells, preventing tumor cells from evading immune detection.
The trade name is Jemperli.
Jemperli is manufactured by GlaxoSmithKline (GSK).
The generic name is Dostarlimab-gxly.
The brand name is Jemperli.
It is manufactured by GlaxoSmithKline in its approved biologics production facilities for global distribution.
Related Products
Tafasitamab‑Cxix
Strength:
200 mg
Form: Injection
Reference Brands: Monjuvi (USA), Minjuvi (EU)
View Details
Dordaviprone Hydrochloride
Strength:
125 mg
Form: Capsules
Reference Brands: Modeyso (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
